Private Advisor Group’s Grace Therapeutics GRCE Stock Holding History

Private Advisor Group’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-625	Closed	-$17K	–	2108
2021 Q2	$17K	Hold	625	–	–	﹤0.01%	1959
2021 Q1	$18K	Hold	625	–	–	﹤0.01%	1873
2020 Q4	$10K	Hold	625	–	–	﹤0.01%	1762
2020 Q3	$14K	Hold	625	–	–	﹤0.01%	1540
2020 Q2	$14K	Sell	625 -104	-14%	-$3.03K	﹤0.01%	2770
2020 Q1	$13K	Sell	729 -84	-10%	-$2.97K	﹤0.01%	1399
2019 Q4	$96K	Sell	813 -312	-28%	-$30.8K	﹤0.01%	1561
2019 Q3	$103K	Buy	1,125 +708	+170%	+$65.6K	﹤0.01%	1582
2019 Q2	$23K	Buy	+417	New	+$18.3K	﹤0.01%	1646

Other funds holding GRCE

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return

SIAP

Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Private Advisor Group's GRCE Position: Q3 2021 in Review

Private Advisor Group sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 625 shares — an estimated $17K sold.

Private Advisor Group first reported a position in GRCE in Q2 2019 and held it in 9 quarters. The position peaked at $103K in Q3 2019. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

Private Advisor Group reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
Private Advisor Group sold 625 Grace Therapeutics shares in Q3 2021, an estimated $17K.
Private Advisor Group first reported a position in Grace Therapeutics in Q2 2019 and held it in 9 quarters.
Private Advisor Group's Grace Therapeutics position peaked at $103K in Q3 2019.
17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Private Advisor Group's 13F filing for Q3 2021, filed 14 Oct 2021.